Atsushi Horiike

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

Ryohei Katayama, Takuya Sakashita, Noriko Yanagitani et al. · EBioMedicine · 2015 · 142 citations · Full text

Medicine, Oncology, Pharmacology +15

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

Tomohide Tamura, Hironobu Minami, Yasuhide Yamada et al. · Journal of Thoracic Oncology · 2006 · 130 citations · Full text

Medicine, Oncology, Pharmacology +7

EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer

Rie Sakakibara, Kentaro Inamura, Yuichi Tambo et al. · Clinical Lung Cancer · 2016 · 130 citations

Medicine, Cancer Biology, Oncology +11

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

Koutaroh Okada, Mitsugu Araki, Takuya Sakashita et al. · EBioMedicine · 2019 · 126 citations · Full text

Medicine, Oncology, Pharmacology +15